Join the Oncology Voice Network. Join for Free
Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)
COVID-19 impact on medical publishing virtual congresses and conferences challenges in medical publications pandemic effect on scientific journals

Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)


Share This Article


Summary

The Coronavirus (COVID-19) pandemic has impacted nearly every facet of our personal and professional lives. Medical publication professionals are facing uncharted territory and uncertainty as to how long the impact will last.

With live congresses being canceled, postponed or transitioned to a virtual format, we must now make decisions to convert presentations to virtual format, ensure embargo and copyright policies are followed, and actively update publication plans. Publications may face delays because authors and peer reviewers are focusing on clinical care, and also because of data availability delays.

Please join us to hear a panel of experts discuss their experiences and views, review our membership survey results, and present case studies to help guide professionals through this unprecedented situation.

At the end of this session, participants should be able to:

  • Be knowledgeable of challenges to medical publishing stemming from the Coronavirus (COVID-19) pandemic
  • Be aware of how congresses and journal publishers are being affected
  • Modify publication plans appropriately in response to changing conditions
  • Maintain good publication practices and ethics in a rapidly shifting environment

Click for Source Download PDF version
COVID-19 impact on medical publishing, virtual congresses and conferences, challenges in medical publications, pandemic effect on scientific journals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Explore OVN